213388-71-7

Basic information

• Product Name: Carbamic acid, [(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI);(3S,4S)-(4-Fluoro-pyrrolidin-3-yl)-carbamic acid tert-butyl ester;(3R,4R)-(4-Fluoro-pyrrolidin-3-yl)-carbamic acid tert-butyl ester;tert-butyl ((3R,4R)-4-fluoropyrrolidin-3-yl)carbamate;Carbamic acid, N-[(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester
• CAS NO: 213388-71-7
• Molecular Formula: C9H17FN2O2
• Molecular Weight: 204.2418832
• Product Categories: N-BOC
• Mol File: 213388-71-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 295.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.18±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, [(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI)(213388-71-7)
• EPA Substance Registry System: Carbamic acid, [(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI)(213388-71-7)

Safety Data

• Hazardous Substances Data: 213388-71-7(Hazardous Substances Data)

Usage

General Description

Carbamic acid, [(3R,4R)-4-fluoro-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C9H17FN2O2. It is an ester of carbamic acid and is composed of a 4-fluoro-3-pyrrolidinyl group and a 1,1-dimethylethyl ester group. This chemical is commonly used in the pharmaceutical industry as a potential drug candidate for the treatment of various medical conditions. Its specific properties and potential applications may vary depending on the intended use and formulation. It is important to handle this chemical with care and follow proper safety guidelines and regulations when working with it in a laboratory or industrial setting.

Relevant articles and documents

Asymmetric Synthesis of cis -(S, R)-3-Amino-4-fluoro-1-methylpyrrolidine

The development of the stereoselective synthesis of cis -(S, R)-3-amino-4-fluoro-1-methylpyrrolidine is described starting from chiral, non-racemic 1-[(3 S,4 S)-3-azido-4-hydroxypyrrolidin-1-yl]-2,2,2-trifluoroethan-1-one. Two sets of deoxyfluorination co

PURINE DERIVATIVES

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Quinolizinone type compounds

Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.